Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease

Recent Patents on CNS Drug Discovery

Volumn 5, Issue 2, 2010, Pages 109-117

  Holscher, Christian ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Alzheimer's disease; Gastric inhibitory polypeptide; Gip; Glp 1; Glucagon like peptide 1; Glucose dependent insulinotropic peptide; Incretins; Neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCAGON LIKE PEPTIDE 1; INSULIN DETEMIR; LIRAGLUTIDE; NERVE GROWTH FACTOR; SOMATOMEDIN C; VASCULOTROPIN;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN FUNCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TRANSPORT; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMALS; BLOOD-BRAIN BARRIER; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; MODELS, NEUROLOGICAL; MOLECULAR SEQUENCE DATA; NEUROPROTECTIVE AGENTS; PATENTS AS TOPIC;

EID: 77953880083     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488910791213130     Document Type: Article

References (105)

1. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187-92.
2. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 2004; 82(8): 510-29.
3. Haan MN. Therapy Insight: Type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol 2006; 2(3): 159-66.
4. Janson J, Laedtke T, Parisi J, O'Brien P, Petersen R, Butler P. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004; 53(2): 474-81.
5. Carro E, Torres-Aleman I. Insulin-like growth factor I and Alzheimer's disease: Therapeutic prospects? Expert Rev Neurother 2004; 4(1): 79-86.
6. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 2004; 490(1-3): 115-25.
7. van Dam P, Aleman A. Insulin-like growth factor-I, cognition and brain aging. Eur J Pharmacol 2004; 490(1-3): 87-95.
8. Cohen AC, Tong M, Wands JR, de la Monte SM. Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. Alcohol Clin Exp Res 2007; 31(9): 1558-73.
9. Li L, Hölscher C. Common pathological processes in Alzheimer Disease and Type 2 Diabetes: A review. Brain Res Rev 2007; 56(2): 384-402.
10. Carro E, Torres AI. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 2004; 490(1-3): 127-33.
11. Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007; 56(7): 1817-24.
12. Steen E, Terry BM, Rivera E, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimer's Dis 2005; 7(1): 63-80.
13. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM. Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer's disease. J Alzheimer's Dis 2006; 9(1): 13-33.
14. Trudeau F, Gagnon S, Massicotte G. Hippocampal synaptic plasticity and glutamate receptor regulation: influences of diabetes mellitus. Eur J Pharmacol 2004; 490(1-3): 177-86.
15. Biessels GJ, De Leeuw FE, Lindeboom J, Barkhof F, Scheltens P. Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J Neurol Neurosurg Psychiatry 2006; 77(3): 304-7.
16. Stockhorst U, de Fries D, Steingrueber HJ, Scherbaum WA. Insulin and the CNS: Effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol Behav 2004; 83(1): 47-54.
17. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 2000; 23(11): 542-9.
18. Biessels GJ, Bravenboer B, Gispen WH. Glucose, insulin and the brain: Modulation of cognition and synaptic plasticity in health and disease: A preface. Eur J Pharmacol 2004; 490: 1-4.
19. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 262-9.
20. Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O'Harte FP. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch Biochem Biophys 2004; 428(2): 136-43.
21. Green BD, Lavery KS, Irwin N, O'Harte FP, Harriott P, Greer B, et al. Novel GLP-1 analogue (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta cell function after 3 weeks daily administration in obese diabetic (ob/ob) mice. J Pharmacol Exp Ther 2006; 318: 914-21.
22. Toso C, McCall M, Emamaullee J, Merani S, Davis J, Edgar R, et al. Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. Transpl Int 2009; [E-Pub ahead of print]
23. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009; 32(7): 1224-30.
24. Pratley RE, Gilbert M. Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Rev Diabet Stud 2008; 5(2): 73-94.
25. Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): Hormone and neurotransmitter. Regul Pept 2005; 128(2): 97-107.
26. Green BD, Gault VA, O'Harte FP, Flatt PR. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr Pharm Des 2004; 10(29): 3651-62.
27. Green BD, Gault VA, O'Harte FP, Flatt PR. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Diabetes Obes Metab 2005; 7(5): 595-604.
28. Vilsboll T, Brock B, Perrild H, Levin K, Lervang HH, Kolendorf K, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008; 25(2): 152-6.
29. Murphy KG, Bloom SR. Nonpeptidic glucagon-like peptide 1 receptor agonists: A magic bullet for diabetes? Proc Natl Acad Sci USA 2007; 104(3): 689-90.
30. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol 2009; 297(1-2): 137-40.
31. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368(9548): 1696-705.
32. Faludi P, Brodows R, Burger J, Ivanyi T, Braun DK. The effect of exenatide re-exposure on safety and efficacy. Peptides 2009; 30(9): 1771-4.
33. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia 2009; 52(10): 2046-55.
34. McClean PL, Gault VA, Harriott P, Holscher C. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010; 630:158-62.
35. Madsen K, Knudsen LB, Agersoe H, Nielsen PF, Thogersen H, Wilken M, et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem 2007; 50(24): 6126-32.
36. Gault VA, Flatt PR, O'Harte FP. Glucose-dependent insulino-tropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun 2003; 308: 207-13.
37. Irwin N, McClean PL, O'Harte FP, Gault VA, Harriott P, Flatt PR. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro(3))GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 2007; 50: 1532-40.
38. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45:1111-9.
39. Gault V, Irwin N, Green B, McCluskey J, Greer B, Bailey C, et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-diabetes. Diabetes 2005; 54(8): 2436-46.
40. Gault VA, Hunter K, Irwin N, Green BD, Greer B, Harriott P, et al. Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists. Arch Biochem Biophys 2007; 461(2): 263-74.
41. Gault VA, Holscher C. Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by Beta-amyloid. J Neurophysiol 2008; 99: 1590-95.
42. Nyberg J, Anderson MF, Meister B, Alborn AM, Strom AK, Brederlau A, et al. Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J Neurosci 2005; 25(7): 1816-25.
43. Hamilton A, Holscher C. Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. Neuroreport 2009; 20(13): 1161-6.
44. Nyberg J, Jacobsson C, Anderson MF, Eriksson PS. Immunohisto-chemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain. J Neurosci Res 2007; 85: 2099-19.
45. Faivre E, McClean P, Hölscher C. Novel GIP analogues cross the BBB and have effects on cognitive processes and synaptic plasticity in the hippocampus. In Annual Conference of the Alzheimer Research Trust UK. abstr 12.1. Southampton, UK (2010).
46. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: Evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995; 7(11): 2294-300.
47. Perry T, Greig NH. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res 2005; 2(3): 377-85.
48. Braak H, Del Tredici K. Alzheimer's disease:Intraneuronal alterations precede insoluble amyloid-beta formation. Neurobiol Aging 2004; 25(6): 713-8; discussion 743-16.
49. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, et al. A novel neurotrophic property of glucagon-like peptide 1: A promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002; 300: 958-66.
50. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003; 72(5): 603-12.
51. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007; 203(2): 293-301.
52. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9: 1173-9.
53. Abbas T, Faivre E, Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res 2009; 205(1): 265-71.
54. Gilman CP, Perry T, Furukawa K, Grieg NH, Egan JM, Mattson MP. Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J Neurochem 2003; 87(5): 1137-44.
55. Holscher C, Li L. New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimer's disease? Neurobiol Aging 2008; DOI: 10.1016/ j.neurobiolaging.2008.08.023.
56. Li L. Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease? Neurosci Bull 2007; 23(1): 58-65.
57. Irwin N, Clarke GC, Green BD, Greer B, Harriott P, Gault VA, et al. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochem Pharmacol 2006; 72(6): 719-28.
58. Hamilton A, Patterson S, Gault V, Holscher C. Novel incretin analogues promote stem cell proliferation in the brains of diabetic mice. In 39th Society for Neurosci Annual Meeting, Chicago, USA, (2009), pp. 529.9.
59. Greenberg DA, Jin K. Neurodegeneration and neurogenesis: Focus on Alzheimer's disease. Curr Alzheimer Res 2006; 3(1): 25-8.
60. Heese K, Low JW, Inoue N. Nerve growth factor, neural stem cells and Alzheimer's disease. Neurosignals 2006; 15(1): 1-12.
61. Mora F, Exposito I, Sanz B, Blazquez E. Selective release of glutamine and glutamic acid produced by perfusion of GLP-1 (7-36) amide in the basal ganglia of the conscious rat. Brain Res Bull 1992; 29(3-4): 359-61.
62. Oka JI, Goto N, Kameyama T. Glucagon-like peptide-1 modu-lates neuronal activity in the rat's hippocampus. Neuroreport 1999; 10(8): 1643-6.
63. Freir DB, Holscher C, Herron CE. Blockade of long-term potentiation by beta-Amyloid peptides in the CA1 region of the rat hippocampus in vivo. J Neurophysiol 2001; 85(2): 708-13.
64. Hölscher C, Gengler S, Gault V, Harriott P, Mallot H. Soluble beta-amyloid [25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur J Pharmacol 2007; 561(1-3): 85-90.
65. Mattson M, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel R. Beta-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992; 12: 376-89.
66. Freir DB, Herron CE. Inhibition of L-type voltage dependent calcium channels causes impairment of long-term potentiation in the hippocampal CA1 region in vivo. Brain Res 2003; 967(1-2): 27-36.
67. Cullen WK, Wu JQ, Anwyl R, Rowan MJ. Beta-amyloid produces a delayed NMDA receptor-dependent reduction in synaptic transmission in rat hippocampus. Neuroreport 1996; 8: 87-92.
68. Xie L, Helmerhorst E, Taddei K, Plewright B, Van BW, Martins R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 2002; 22(10): RC221.
69. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 2007.
70. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 2008; 22(1): 246-60.
71. Gengler S, Gault V, Harriott P, Hölscher C. Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25-35) are dependent on stimulation-protocol and genetic background. Exp Brain Res 2007; 179(4): 621-30.
72. Gault V, Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 2008; 587(1-3): 112-7.
73. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003; 100(18): 10417-22.
74. Oka J, Suzuki E, Kondo Y. Endogenous GLP-1 is involved in beta-amyloid protein-induced memory impairment and hippocampal neuronal death in rats. Brain Res 2000; 878(1-2): 194-8.
75. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006; 7(9): 940-6.
76. Gengler S, McClean P, McCurtin R, Gault V, Holscher C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core amyloid plaque load in an APP/PS1 mouse model of Alzheimer's disease. Neurobiol Aging 2010 (in press).
77. McClean P, Pathasarthy V, Gault V, Holscher C. Liraglutide, a novel GLP-1 analogue, prevents the impairment of learning and LTP in an APP/PS-1 mouse model of Alzheimer's disease. In ICAD Annual Conference, abstr. 103 Hawaii, USA, (2010).
78. Begley DJ. Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacol Ther 2004; 104(1): 29-45.
79. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002; 18(1-2): 7-14.
80. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003; 27(3): 313-8.
81. McClean P, Fung K, McCurtin R, Gault V, Hölscher C. Novel GLP-1 analogues cross the blood brain barrier: a link between diabetes and Alzheimer's disease. In Society for Neuroscience Annual Meeting. abstr. 529.8 Chicago, USA, (2009).
82. Banks WA. The source of cerebral insulin. Eur J Pharmacol 2004; 490(1-3): 5-12.
83. Hallschmid M, Schultes B. Central nervous insulin resistance: A promising target in the treatment of metabolic and cognitive disorders? Diabetologia 2009; 52(11): 2264-9.
84. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA 2009; 106(32):13594-9
85. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009; 15: 331-7.
86. Poon WW, Blurton-Jones M, Tu CH, Feinberg LM, Chabrier MA, Harris JW, et al. beta-Amyloid impairs axonal BDNF retrograde trafficking. Neurobiol Aging 2009; [Epub ahead of print].
87. Schulte-Herbruggen O, Braun A, Rochlitzer S, Jockers-Scherubl MC, Hellweg R. Neurotrophic factors--a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmuno-logical diseases? Curr Med Chem 2007; 14(22): 2318-29.
88. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 2009; 5: 311-22.
89. Clarris HJ, Nurcombe V, Small DH, Beyreuther K, Masters CL. Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer's disease from hippocampal explants. J Neurosci Res 1994; 38(3): 248-58.
90. Kordower JH, Mufson EJ, Fox N, Martel L, Emerich DF. Cellular delivery of NGF does not alter the expression of beta-amyloid immunoreactivity in young or aged nonhuman primates. Exp Neurol 1997; 145(2): 586-91.
91. Covaceuszach S, Capsoni S, Ugolini G, Spirito F, Vignone D, Cattaneo A. Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr Alzheimer Res 2009; 6(2): 158-70.
92. Bradbury J. Hope for AD with NGF gene-therapy trial. Lancet Neurol 2005; 4(6): 335.
93. Nagano I, Shiote M, Murakami T, Kamada H, Hamakawa Y, Matsubara E, et al. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neruol Res 2005; 27(7): 768-72.
94. Shi L, Linville MC, Tucker EW, Sonntag WE, Brunso-Bechtold JK. Differential effects of aging and insulin-like growth factor-1 on synapses in CA1 of rat hippocampus. Cereb Cortex 2005; 15: 571-7.
95. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429: 413-7.
96. Lee HJ, Kim KS, Park IH, Kim SU. Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model. PLoS One 2007; 2: e156.
97. Hwang DH, Lee HJ, Park IH, Seok JI, Kim BG, Joo IS, et al. Intrathecal transplantation of human neural stem cells over- expressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther 2009; 16(10): 1234-44.
98. Aubert-Pouessel A, Venier-Julienne MC, Clavreul A, Sergent M, Jollivet C, Montero-Menei CN, et al. In vitro study of GDNF release from biodegradable PLGA microspheres. J Control Release 2004; 95(3): 463-75.
99. Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008; 71(22): 1770-5.
100. Terzi D, Zachariou V. Adeno-associated virus-mediated gene delivery approaches for the treatment of CNS disorders. Biotechnol J 2008; 3(12): 1555-63.
101. Gregory-Evans K, Chang F, Hodges MD, Gregory-Evans CY. Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration. Mol Vis 2009; 15: 962-73.
102. Greig, N., Egan, J., Doyle, M., Holloway, H., Perry, T.A. GLP-1 exendin-4 peptide analogs and uses thereof. US7576050 (2009).
103. Flatt, P.R., Holscher, C., Gault, V.A. Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission. WO2009030499A1 (2009).
104. Bevec, D., Cavalli, F., Cavalli, V., Bacher, G. Use of a peptide as a therapeutic agent. WO2009039964 A2 (2009).
105. Flatt, P.R., Holscher, C., Gault, V.A. Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission. WO2009030498A2 (2009).